Prostaglandin Analog international drug patents, generic suppliers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Meitheal	ALPROSTADIL	alprostadil	INJECTABLE;INJECTION	075196-001	Apr 30, 1999	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Alembic	BIMATOPROST	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	210263-001	Apr 12, 2019	AT	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Mankind Pharma	BIMATOPROST	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	218196-001	Mar 17, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: June 10, 2026

Prostaglandin analogs dominate first-line glaucoma and ocular hypertension pharmacotherapy in many markets, driven by once-daily dosing, strong intraocular pressure (IOP) lowering, and incremental formulation differentiation. The patent landscape is segmented: (1) foundational compounds and early clinical-use claims with staggered expiry across active ingredients, (2) formulation and delivery-system patents (preservative systems, chelating agents, buffers, sustained-release concepts), and (3) method-of-use and device-adjacent claims (dose regimens, tolerability, combination regimens). In the current cycle, market dynamics center on loss of exclusivity for specific lineages, ongoing generic launches and label expansions, and pay-for-delay settlement history that shapes Paragraph IV risk.

What patents protect prostaglandin analog glaucoma drugs (latanoprost, bimatoprost, travoprost, tafluprost, unoprostone)?

Answer: Patent protection typically clusters around (a) active ingredient composition claims (early filings), (b) ocular formulation composition claims (buffers, surfactants, preservative systems), (c) method-of-use claims for IOP reduction and glaucoma patient subsets, and (d) sometimes delivery or device-adjacent innovations. For most legacy prostaglandins, the most enforceable value is now in formulation and method-of-use estates and in Orange Book-listed secondary patents tied to branded formulations.

Patent clusters by active ingredient lineage

Latanoprost (and latanoprostene-related differentiators)

Core estate: composition-of-matter for latanoprost (and some stereochemical/derivative claims depending on jurisdiction and filing strategy).
Second-wave estate: formulation claims tied to pH, solubilizers and surfactant selection, preservative system (e.g., benzalkonium chloride approaches), and osmolarity adjustments.
Regimen/method: dosing timing (typically once daily at night), IOP-lowering claims, and sometimes responder subgroups.

Bimatoprost

Core estate: composition-of-matter for bimatoprost.
Formulation estate: buffer system and preservative choices, and solubility stabilization strategies.
Method-of-use: IOP reduction claims by specific dosing schedules.

Travoprost

Core estate: composition-of-matter and salt/derivative claims as applicable.
Formulation estate: solubilization and stabilization chemistry, preservative and tonicity design.

Tafluprost

Core estate: composition-of-matter.
Formulation estate: preservative system strategy and vehicle composition.

Unoprostone (non-prostanoid lipid mediator)

Core estate: composition-of-matter.
Formulation and method-of-use: ocular vehicle and dosing regimen claims.

How protection is typically structured for litigation readiness

Orange Book secondary patents usually include formulation and method-of-use claims tied to the NDA.
Strong enforcement tends to follow patents that are listed for the marketed NDA strength(s), not only broad compound patents.

How many patents cover prostaglandin analog drugs in the Orange Book, and which are formulation vs method-of-use?

Answer: Orange Book coverage for prostaglandin analogs is commonly dominated by secondary, product-specific patents (formulation and method-of-use). The exact count varies by NDA and branded strength, but the risk profile is driven by how many Orange Book patents remain enforceable at the time of generic filing.

FeaturedSnippet-style breakdown: what tends to be listed

Formulation patents
- vehicle and buffer system (pH, ionic strength)
- surfactant selection
- preservative system design
Method-of-use patents
- dosing frequency (once daily)
- use for ocular hypertension vs glaucoma
- patient subpopulations and treatment targets
Manufacturing or process patents
- less common as enforceable Orange Book listings for older prostaglandin analogs, but present in some estates.

Patent estate density pattern across the class

Older introductions often have:
- diminished compound patent life (expired or near-expired)
- residual formulation/method-of-use life
Newer branded reformulations often have:
- fewer remaining foundational patents
- more remaining product-specific secondary patents.

When do prostaglandin analog drugs lose exclusivity in the US (patent expiration and regulatory exclusivity)?

Answer: Exclusivity timing is ingredient-specific and NDA-specific, with two main layers:

patent expiry for listed patents, and
any regulatory exclusivity that could delay approval of generic copies.

What sets the practical generic entry window

Earliest US patent expiry that clears all Orange Book listed patents for the NDA/strength.
Last-to-expire secondary patents often block generic launch until they end or are designed around.
Regulatory exclusivity (when applicable) can extend the time to market even after primary patents expire.

Market timing implications

A wave of generic competition typically follows:
- last-enforceable Orange Book patent expiry
- AND resolution of any Paragraph IV litigation that delays FDA approval.

Which generic entry risks exist for prostaglandin analogs, and how do Paragraph IV challenges play out?

Answer: Generic entry risk is driven by whether a generic filer can:

maintain a design-around strategy for formulation and method patents, and
avoid an injunction risk in litigation tied to remaining Orange Book-listed patents.

Typical Paragraph IV risk vectors in this class

Formulation similarity triggers obviousness and equivalence arguments.
Preservative system changes can be both a scientific and legal design-around lever.
Dosing regimen claims create a “use claims” litigation pathway even for the same active ingredient.

Pay-for-delay and settlement dynamics

Patent settlement history in ophthalmology often leads to:
- agreed “at-risk launch” windows,
- payment consideration structures,
- limited carveouts or launch triggers tied to specific patent expiry dates.
For the prostaglandin analog class, these deals are usually anchored to the last enforceable secondary patents.

How does bimatoprost compare with latanoprost and travoprost in patent strength and barriers to generic entry?

Answer: Across the class, barriers to generic entry are rarely driven by compound patents alone once time has passed; they are usually driven by:

remaining formulation and method-of-use patents,
NDA-specific secondary patents,
and settlement-driven launch dates.

Comparative matrix: where differentiation tends to matter legally

Active ingredient	Legal differentiation mechanism	Typical barrier source	Generic strategy lever
Bimatoprost	Vehicle/pH/preservative and method-of-use	product formulation and dosing regimen patents	change vehicle and preserve system; certify to carve out method claims
Latanoprost	vehicle and regimen; preservative design	late-cycle secondary patents	design-around formulation; ensure label avoids method-of-use trigger
Travoprost	stabilization and solubilization system	product formulation patents	different buffers/solubilizers; certification path to remaining patents
Tafluprost	preservative and vehicle design	product formulation and tolerability-related claims	preservative system design around
Unoprostone	vehicle and method	method-of-use claims	dosing-label and formulation design

What formulations are protected by prostaglandin analog patents (preservative-free, different buffers, solubility systems)?

Answer: Formulation patents typically protect ocular vehicle architecture, not just the active ingredient. Key protectable variables include preservative systems, buffers, pH, and solubilizers.

Formulation features that often map to protectable claim scope

Preservative systems (including benzalkonium chloride variants or alternatives)
pH and buffer choices that stabilize the prostaglandin
Surfactants and tonicity agents
Vehicle composition that supports ocular tolerance and stable shelf life

Practical design-around opportunities

Switching preservatives or buffers can avoid literal claim coverage, but equivalence arguments can still drive litigation.
The strongest barrier is when formulation patents are tightly linked to the marketed product’s NDA and have robust claim language.

Which method-of-use claims are common for prostaglandin analogs (once-daily dosing, ocular hypertension vs glaucoma)?

Answer: Method-of-use estates usually center on:

once-daily dosing regimens,
use for IOP reduction in glaucoma/ocular hypertension,
and treatment outcomes tied to specified clinical targets.

Litigation-relevant claim patterns

Claims that specify dosing time or schedule can be triggered by product labeling.
Broader use claims increase litigation risk but often narrow after earlier claim interpretation or prosecution history.

Label and FDA labeling interplay

Even when a generic product is pharmaceutically equivalent, label language can determine whether method-of-use claims are implicated.
Generics often use paragraph IV certifications tied to non-infringement/invalidity for use claims.

What patent litigation affects prostaglandin analog generics (involvement of major ophthalmic generic companies)?

Answer: The prostaglandin analog space sees ongoing litigation tied to:

Orange Book secondary patents,
settlement terms that delay or structure generic launches, and
injunction disputes around remaining enforceable claims.

Litigation targets in the class

formulation patents tied to the branded NDA
method-of-use patents tied to dosing regimens
sometimes manufacturing process patents tied to the marketed product’s stability and release profile

Settlement-driven launch structuring

Common settlement constructs:

delayed launch until a date tied to last enforceable patent
carveouts for specific strengths or package configurations
label modifications to reduce use-claim exposure

What is the Orange Book status of prostaglandin analog products (listed patents and “expiration stack” view)?

Answer: Orange Book status is best viewed as an “expiration stack” where multiple secondary patents end at different dates; the last-to-expire patent often governs the first eligible launch.

How to interpret expiration stacks for launch planning

Determine, for each branded NDA/strength:
- the number of listed patents
- each patent’s stated expiration date
- which patents are foundational vs formulation vs method-of-use
Launch feasibility requires clearance for every listed patent that the applicant cannot work around or successfully challenge.

How do combination products with prostaglandin analogs change the patent landscape?

Answer: Combination therapies shift the patent focus from single-agent formulation to:

fixed-dose combination compositions,
combined dosing regimens,
and combination-specific method-of-use claims.

Why combinations complicate generic entry

Even if the prostaglandin component’s compound patents have expired, combination patents can remain enforceable.
Generics may face additional formulation equivalence litigation for the multi-API vehicle.

Which companies are positioned for prostaglandin analog generic entry, and how do settlements shape the competitive landscape?

Answer: Competitive pressure comes from ophthalmic-focused generics and established multi-product manufacturers with proven ability to certify, litigate, and launch at scale. Settlement patterns in the class typically determine:

when generics reach full market penetration,
whether branded incumbents retain price premiums longer,
and which SKUs see earlier supply.

Competitive pattern after last-patent expiry

First wave: lower-priced generics capture share quickly where bioequivalence and formulation claims are cleared.
Second wave: additional strengths, package forms, and label refinements expand availability.

What revenue exposure do brand incumbents have when prostaglandin analog exclusivity ends?

Answer: Revenue exposure is usually highest when:

multiple competitors can launch generic copies simultaneously, or
settlement agreements align launch dates across strengths and package configurations.

Revenue mechanics

Loss of exclusivity typically leads to:
- accelerated price compression,
- increased payer pressure,
- and reallocation to formularies favoring lowest net price.

Key Takeaways

Prostaglandin analog exclusivity is increasingly governed by Orange Book-listed secondary patents tied to formulation and method-of-use, not only original compound protection.
Market timing for generic entry follows the last-to-expire patent on the NDA/strength “expiration stack,” often shaped further by Paragraph IV litigation and settlements.
Formulation variables like preservative systems, buffers, and vehicle stabilization are the most common legal battlegrounds, while once-daily dosing and glaucoma/ocular hypertension use drive method-of-use exposure.
Competitive outcomes depend on how many patents remain enforceable per NDA strength and whether design-arounds can avoid both literal infringement and equivalence theories.

FAQs

1) How do prostaglandin analog preservative changes affect patent infringement risk?
Formulation patents tied to vehicle architecture can be implicated by preservative substitution, so generics must align certification positions and label positioning with the scope of Orange Book formulation claims.

2) Can a generic prostaglandin analog launch while method-of-use patents still exist?
A launch is feasible only if the generic’s Paragraph IV certifications can avoid infringement theories for the remaining method-of-use patents, often via label design that mitigates use-claim triggers.

3) Why do fixed-dose combinations with prostaglandin analogs show different generic risk than monotherapies?
Combination products add protectable fixed-dose composition and combination regimen claims, extending barriers even when the prostaglandin component’s foundational patents have expired.

4) What matters more for generic timing: compound patent expiry or Orange Book secondary patents?
Orange Book secondary patents typically matter more because they are directly tied to the marketed product NDA and govern whether the FDA can approve generics without unresolved exclusivity or blocking litigation.

5) How do settlement agreements typically change launch dates for prostaglandin analog competitors?
Settlements often set structured launch windows tied to specific remaining patents, including carveouts by strength and package, which delay full entry until the last enforceable patent or agreed triggers.

References (APA)

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-06-10).
FDA. Guidance for Industry: Patent and Exclusivity Information for Drugs. U.S. Food and Drug Administration. https://www.fda.gov/ (accessed 2026-06-10).